Document is current
Any future updates will be listed below
-
Authors
Lim, Bram S. J. https://orcid.org/0000-0002-8763-6436
Whitfield, Holly J. https://orcid.org/0000-0002-7282-387X
Trinh, Mi K. https://orcid.org/0000-0003-4185-0071
Bloye, Gianna
Thomas, Rebecca
Anderson, Nathaniel D. https://orcid.org/0000-0003-4523-6327
Wenger, Anna https://orcid.org/0000-0001-6063-5401
Hodder, Angus
Treger, Taryn D.
Lee-Six, Henry https://orcid.org/0000-0003-4831-8088
Coorens, Tim H. H. https://orcid.org/0000-0002-5826-3554
Parks, Conor https://orcid.org/0000-0003-0240-0684
Ogbonnah, Toochi
Pölönen, Petri https://orcid.org/0000-0001-6128-9985
Mullighan, Charles G. https://orcid.org/0000-0002-1871-1850
Teachey, David T. https://orcid.org/0000-0001-7373-8987
Xu, Jason
Tan, Kai https://orcid.org/0000-0002-9104-5567
Hagleitner, Melanie
Kester, Lennart https://orcid.org/0000-0002-8259-9971
van Leeuwen, Frank N. https://orcid.org/0000-0003-1107-6513
Beattie, Gordon
Mansour, Marc R. https://orcid.org/0000-0001-6835-3791
Williams, Owen https://orcid.org/0000-0002-1760-6880
Bartram, Jack https://orcid.org/0000-0003-1573-2506
Adams, Stuart https://orcid.org/0000-0002-2650-2848
Jardine, Laura https://orcid.org/0000-0003-4495-8205
Behjati, Sam https://orcid.org/0000-0002-6600-7665
O’Connor, David https://orcid.org/0000-0003-3542-5976
-
Funding
Funding for this research was provided by:
Wellcome Trust (108413/A/15/D)
- License Information
-
More Information
Article History
Received: 27 April 2025
Accepted: 1 October 2025
First Online: 12 November 2025
Competing interests
: D.T.T. receives research funding from BEAM Therapeutics and Neoimmune Tech. D.T.T. serves on advisory boards (unpaid) for Amgen, BEAM Therapeutics, Novartis, Jazz, J&J Innovation, Pfizer, Sobi, Servier and Syndax. D.T.T. holds patents or has patents pending: “Biomarkers predictive of cytokine release syndrome” (US11747346) and “Compositions and methods comprising anti-CD38 chimeric antigen receptors” (US20250121004, pending). C.G.M. receives research funding from AbbVie and Pfizer. C.G.M. has a consulting role with Amgen and Illumina. C.G.M. receives royalties from Cyrus. The remaining authors declare no competing interests.
